Stephanie Farnia
YOU?
Author Swipe
View article: ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies Open
View article: Nomenclature for Cellular and Genetic Therapies: A Need for Standardization
Nomenclature for Cellular and Genetic Therapies: A Need for Standardization Open
View article: Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities
Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities Open
Chimeric antigen receptor (CAR) T‐cell therapy is a major advancement in the treatment of lymphoid malignancies, especially diffuse large B‐cell lymphoma and acute lymphoblastic leukemia (ALL). Since the U.S. Food and Drug Administration (…
View article: Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome Open
ClinicalTrials.gov identifier: NCT01166009.
View article: Chimeric Antigen Receptor T-Cell Therapy
Chimeric Antigen Receptor T-Cell Therapy Open
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non…
View article: Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients
Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients Open
Patient-centered medical home models are fundamental to the advanced alternative payment models defined in the Medicare Access and Children's Health Insurance Plan Reauthorization Act (MACRA). The patient-centered medical home is a model o…
View article: Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access
Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access Open
Cellular therapies and other regenerative medicines are emerging as potentially transformative additions to modern medicine, but likely at a staggering financial cost. Public health care systems’ budgets are already strained by growing and…
View article: Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients
Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients Open
Hematopoietic cell transplantation (HCT) is an expensive, medically complicated, and potentially life-threatening therapy for multiple hematologic and nonhematologic disorders with a prolonged trajectory of recovery. Similar to financial i…
View article: National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report
National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report Open
Hematopoietic cell transplantation (HCT) survivors are at risk for development of late complications and require lifelong monitoring for screening and prevention of late effects. There is an increasing appreciation of the issues related to…
View article: Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities
Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities Open
View article: Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease
Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease Open
Although a number of published trials exist of HLA-identical sibling hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) that span 2 decades, when and for whom this therapy should be pursued is a subject of debate. Asses…
View article: Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups Open
View article: Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation Open
View article: Goals for Pay for Performance in Hematopoietic Cell Transplantation: A Primer
Goals for Pay for Performance in Hematopoietic Cell Transplantation: A Primer Open
Bundled payments for hematopoietic cell transplantation (HCT) have long been accepted by both commercial health insurance providers and transplant centers, effectively outpacing the use of this payment model elsewhere in health care. As wi…
View article: Guidelines for Defining and Implementing Standard Episode of Care for Hematopoietic Stem Cell Transplantation within the Context of Clinical Trials
Guidelines for Defining and Implementing Standard Episode of Care for Hematopoietic Stem Cell Transplantation within the Context of Clinical Trials Open
The Patient Protection and Affordable Care Act requires that health care insurers cover routine patient costs associated with participating in clinical trials for cancer and other life-threatening diseases. There is a need to better define…